Increased Toll-Like Receptor Activity in Patients With Metabolic Syndrome
- Ishwarlal Jialal, MD, PHD1⇓,
- Beverley A. Huet, PHD2,
- Harmeet Kaur, PHD1,
- Alexander Chien, BS1 and
- Sridevi Devaraj, PHD3
- 1Laboratory of Atherosclerosis and Metabolic Research, University of California Davis Medical Center, Sacramento, California
- 2Department of Biostatistics, University of Texas Southwestern Medical Center, Dallas, Texas
- 3Department of Pathology, Texas Children’s Hospital and Baylor College of Medicine, Houston, Texas
- Corresponding author: Ishwarlal Jialal, .
OBJECTIVE The metabolic syndrome (MetS) is highly prevalent and confers an increased risk for diabetes and cardiovascular disease (CVD). While MetS is a proinflammatory state, there is a paucity of data on cellular inflammation in MetS. Toll-like receptors (TLRs) are classical pattern recognition receptors of the innate immune response.
RESEARCH DESIGN AND METHODS The aim of this study was to examine monocyte TLR2 and TLR4 in MetS patients without diabetes or CVD and control subjects since both of the receptors have been implicated in atherosclerosis and insulin resistance. Fasting blood was obtained for TLR expression and activity.
RESULTS Circulating levels of high-sensitivity C-reactive protein, interleukin (IL)-1β, IL-6, IL-8, and soluble tumor necrosis factor receptor 1 (sTNFR1) were significantly increased in MetS versus control subjects following adjustment for waist circumference. There was a significant increase in both TLR2 and TLR4 surface expression and mRNA on monocytes after adjustment for waist circumference. In addition to increased nuclear factor-κB nuclear binding, there was significantly increased release of IL-1β, IL-6, and IL-8 in MetS versus control subjects following priming of the monocytes with lipopolysaccharides. While both plasma free fatty acids and endotoxin were increased in MetS, they correlated significantly with TLR4 only.
CONCLUSIONS In conclusion, we make the novel observation that both TLR2 and TLR4 expression and activity are increased in the monocytes of patients with MetS and could contribute to increased risk for diabetes and CVD.
- Received December 6, 2011.
- Accepted January 19, 2012.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.